Therapy Areas: AIDS & HIV
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
15 October 2025 - Biopharmaceutical company Merck (NYSE: MRK), known as MSD outside the US and Canada, reported on Wednesday that it has presented new data from two Phase 3 studies evaluating its inve...
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
19 September 2025 - AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company, announced on Thursday that it has completed patient en...
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
26 August 2025 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Tuesday that the European Commission has granted marketing authorization for Yeytuo (lenacapavir), a twice-yea...
Gilead receives positive CHMP opinions for lenacapavir as first twice-yearly HIV prevention option in EU
25 July 2025 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that it has received a positive opinion from the Committee for Medicinal Products for Human Use of the Eu...
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
14 July 2025 - HIV medication company Gilead Sciences Inc (Nasdaq: GILD) reported on Monday that it has presented new data at IAS 2025 from its Phase 3 PURPOSE trials, confirming the efficacy and tole...
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
14 July 2025 - Biopharmaceutical company Merck & Co, Inc (NYSE: MRK), known as MSD outside the US and Canada, announced on Monday that it will initiate Phase 3 clinical trials for MK-8527, an inve...